The New Diabetes Drug of Novo Nordisk A/S (NVO) Get Approval by FDA
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care.
On Nov. 8, 2012, the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) completed the New Drug Application (NDA) for insulin degludec and insulin degludec/insulin aspart meeting regarding Novo Nordisk. The Committee gave positive approval and support for its new diabetes drug. But it was also asked to conduct a post-approval cardiovascular outcomes trail since the drug might cause a lower rate of hypoglycemia and potential cardiovascular risk.
The FDA has not informed Novo Nordisk of when it expects to complete its review of the NDAs.Tags: NVO, Diabetes Drug, FDA, Insulin Degludec, Insulin Aspart